12.08.2021 • News

Diversey Buys Tasman Chemicals

Diversey Holdings, a US-headquartered provider of hygiene, infection prevention and cleaning products, has entered into an agreement to buy Australia’s Tasman Chemicals. Financial terms were not revealed. Headquartered in Melbourne, Tasman manufactures professional hygiene and cleaning products to the institutional and food & beverage sectors.

Tasman’s manufacturing infrastructure, in particular, “provides exciting opportunities to integrate our business and expand our product offering,” Diversey said. CEO Phil Wieland noted that the acquisition “provides us with a strong manufacturing footprint, allowing for greater operational flexibility and responsiveness to customer requirements. In addition, “the strong reputation of Tasman will enable us to grow our position in the Australia and New Zealand markets.”

Diversey did not say when it expects the transaction to close.

The Tasman buy follows Diversy’s takeover of Poland’s SaneChem last December, which the company said cements its market-leading position in the Polish market while also strengthening its growth plans for eastern Europe in the core food & beverage markets of brewing, beverage, processed food, dairy, agriculture and pharmaceuticals.

Author: Elaine Burridge, Freelance Journalist

US-based Diversey Holdings has entered into an agreement to buy Australia’s...
US-based Diversey Holdings has entered into an agreement to buy Australia’s Tasman Chemicals for an undisclosed sum. Headquartered in Melbourne, Tasman manufactures professional hygiene and cleaning products to the institutional and food & beverage sectors. (c) Tasman Chemicals

From Catalogue to Collaboration

Enamine's Expert Insights Collection Is Free to Download
Enamine’s 35 Years of Advancing Drug Discovery

Enamine's Expert Insights Collection Is Free to Download

From catalogue to collaboration — explore 35 years of drug discovery breakthroughs, novel building blocks, and the science shaping tomorrow's medicines. Download your complimentary copy now.

Expert Insights

ADCs for Precision Cancer Therapy
Comprehensive Insights into Antibody–Drug Conjugates

ADCs for Precision Cancer Therapy

Explore how antibody-drug conjugates are reshaping precision cancer therapy and discover what it takes to successfully develop, manufacture, and scale these complex biologics.

most read